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Summary
Background: The desert horned vipers (Cerastes
cerastes and C. gasperettii) are the most familiar
snakes of the great deserts of North Africa and
the Middle East, including the plains of Iraq. They
are responsible for many human snake bites. In
Western countries, they are popular among exotic-
snake keepers.
Aim: To investigate mechanisms of life-threatening
envenoming and treatment.
Design: Clinical investigation.
Methods: Clinical and laboratory studies with
measurement of serum venom antigen concentra-
tions by enzyme immunoassay.
Results: Two men bitten while handling cap-
tive Saharan horned vipers (Cerastes cerastes) in
Europe developed extensive local swelling and
life-threatening systemic envenoming, characterized
by coagulopathy, increased fibrinolysis, thrombo-
cytopenia, micro-angiopathic haemolytic anaemia
and acute renal failure. The clinical picture is expli-
cable by the presence in C. cerastes venom of several
thrombin-like, Factor-X-activating, platelet-aggre-
gating, haemorrhagic and nephrotoxic components.
In one case, prophylactic use of subcutaneous
epinephrine may have contributed to intracranial
haemorrhage. The roles in treatment of heparin
(rejected) and specific antivenom (recommended)
are discussed.
Discussion: Cerastes cerastes is capable of life-
threatening envenoming in humans. Optimal treat-
ment of envenoming is by early administration of
specific antivenom, and avoidance of ineffective
and potentially-dangerous ancillary methods.
Introduction
The desert horned vipers (genus Cerastes) are the
best known, most distinctive and most abundant
venomous snakes of the great deserts of North
Africa and the Middle East; from Morocco in the
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west, east to Iraq and western Iran, and south to the
Sudan. In Arabia, it is one of the most frequently
observed snakes despite its nocturnal habit;1 in
Dharan, Saudi Arabia, it was responsible for most
of a series of 26 cases of snake bite;2 and on the
plains of Iraq, it is the commonest snake.3 In Egypt,
C. cerastes was depicted in pre-dynastic times
(>3000 BC),4,5 and was represented by the phonetic
hieroglyph ‘f’ or ‘fy ’ in inscriptions and papyri.6
Whether Cleopatra used a snake as the instrument
of her suicide has been long debated.7,8 Some
favour the idea that she chose C. cerastes, but
its venom is insufficiently potent, rapid and reliable.
A more plausible candidate is the Egyptian cobra
or ‘asp’ (Naja haje). In the 5th century AD, the
Greek historian Herodotus found that at Thebes
in Upper Egypt, horned vipers were deemed sacred9
and their bodies were embalmed.10 These snakes
have captured the attention of desert travellers
from the time of James Bruce of Kinnaird in the
18th century7,11 to Doughty, Philby and Thesiger
in the 20th.12
The genus Cerastes (Viperinae) comprises three
species of desert vipers: C. cerastes (Saharan horned
viper) (Figure 1) distributed across North Africa as far
as south-western Israel and also in south-western
Arabia; C. gasperettii (Gasperetti’s horned viper),
from the Arava Valley of south-eastern Israel, east
through the Arabian peninsula to western Iran; and
C. vipera (Saharan sand-viper), a much smaller
species which never has supraocular horns.13,14 In
the past, C. cerastes and C. gasperettii were known by
many other scientific names, including C. cornutus, C.
aegyptiacus, and Aspis cerastes. Until now, no distinc-
tion has been made between the venoms of C. cerastes
and C. gasperettii in the medical or toxinological
literature but, in the present paper, attribution has
been inferred reliably from the known geographical
distribution of the two species, accepting their
sympatry in south-western Arabia. A hornless sub-
species C. c. mutila, inhabiting the western Sahara,
was proposed by Doumergue.14 However, this
feature is now regarded as merely a polymorphism
and the subspecies is no longer recognized.15
In the 19th century, C. cerastes had a bad repu-
tation among French military surgeons in Algeria
(see below). Doumergue (1901)15 considered its
bite potentially lethal, Calmette (1908)16 thought it
responsible for frequent fatal accidents and Phisalix
(1922)17 noted that its bite could kill many different
species including horses, camels and pigeons.
However, Corkill (1935) wrote that ‘This species
is of wide distribution, frequent occurrence, evil
reputation and fierce behaviour, yet not a single
thoroughly authenticated fatal case of poisoning
resulting from its bite has been published.‘18 This
echoed the opinion of the Egyptian physicians
who wrote the earliest known account of the treat-
ment of snake bite, the Brooklyn Museum Papyri,
dating perhaps from 2200 BC. They regarded bites
by horned vipers ‘fy ’ as non-lethal, as the victims
could be saved.6,19
Figure 1. Saharan horned viper (Cerastes cerastes).
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In the face of such a historical depth of medical
opinion, we were surprised to be confronted by
two cases of potentially fatal envenoming caused
by captive specimens of the Saharan horned viper
(C. cerastes). We attempt to attribute the underlying
pathophysiological mechanisms to known constitu-
ents of the venom of this fabulous snake.
Case histories
Patient 1
A 63-year-old retired car salesman, presented to
Chur regional hospital, Switzerland, on 19 May
2001 at 1400 h. One and a half hours earlier,
he had been bitten on the index finger of his left
hand by his pet Saharan horned viper, which he
designated ‘Cerastes cerastes mutila’ (Figure 2). This
snake, captive-bred (F2) from southern Moroccan
stock, was 7 years old and 60 cm in total length.
The patient had been bitten by a Vipera raddei
30 years earlier, but had not been given antivenom.
He felt well. There were two visible fang punc-
tures. Results of routine haematological tests, includ-
ing tests of blood coagulation, were completely
normal. However, over the next 6 hours, swelling
extended throughout the arm. He became fatigued
and nauseated, and he vomited. Five and a half
hours after the bite, an area of necrosis 1.5 cm in
diameter was discernible at the bite, and there was
evidence of coagulopathy: International Normalized
Ratio (INR) 2.4, PTT 67 s, fibrinogen 0.3 g/l.
He was referred to the University Hospital of
Zu¨rich, arriving 8 h after the bite. The serum
C. cerastes venom antigen concentration, measured
later by enzyme-immuno-assay in Liverpool, was
36.5 ng/ml.20 Ten and a half hours after the bite,
he received, over 1 h, 50ml of Antirept (Pasteur
Me´rieux Lyon-France se´rum antivenimeux, poly-
valent, purifie´: moyen orient-afrique du nord), an
equine antivenom with activity against C. cerastes
venom. Epinephrine (0.25mg) was injected sub-
cutaneously as prophylaxis a few minutes before-
hand and, 30 min after the antivenom, he was given
100mg of prednisolone intravenously, because he
had developed nausea, suggesting an anaphylactoid
reaction. Two hours after starting antivenom, his
serum venom antigen concentration had dropped to
2.2 ng/ml.
Initial laboratory findings showed undetectable
plasma fibrinogen, prolonged prothrombin time
(>200 s, INR 5.1), prolonged APTT (>200 s), pro-
longed thrombin time (>200 s), low factor II activity
(54%; normal range 60–150%), very low factor V
activity and thrombocytopenia (Table 1). Factor VII
and factor VIII activities were normal and anti-
thrombin III activity was slightly diminished (73%;
normal range 75–120%). D-dimers were slightly
elevated (Table 1). On admission, his urine con-
tained erythrocytes but no leukocytes or casts. The
patient received 2 g of fibrinogen, 4 units of fresh
frozen plasma and six units of platelets.
Over the next 12 h, prothrombin time, factor V
and fibrinogen had returned to normal (Table 1).
However, haemolytic anaemia developed (Table 1),
LDH peaked at 8136U/l on day 5 and hapto-
globin levels were low from day 1 onwards, with
a nadir of <1mg/dl on day 5). Fragmented eryth-
rocytes were seen on day 1 and persisted until
day 11. These findings were compatible with
micro-angiopathic haemolysis. Intravenous heparin
(10 000 units/24 h) was given for one day starting on
Figure 2. Saharan horned viper (Cerastes cerastes) lacking supra-ocular horns and responsible for biting Patient 1.
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day 2, in an attempt to inhibit thrombin formation
(see Discussion).
There was a persistent profound thrombocytope-
nia and evidence of increased fibrinolysis (Table 1),
fibrinogen degradation products 7400 ng/l (normal
values <500 ng/l) and rhabdomyolysis (creatine
kinase maximum 7873 U/l with a low CK-MB
isoenzyme peaking at 109U/l on day 4, myoglobin
2874 mg/l). Myocardial damage was suggested by
a troponin T level of 1.6 mg/l, although the electro-
cardiogram remained normal apart from a sinus
tachycardia. A beta-blocker was started for sus-
pected ischaemic heart disease.
He remained haemodynamically stable, but was
virtually anuric. Biochemical evidence of acute
renal failure developed over the first 48 h requiring
haemodialysis. Because of the evidence of persis-
tently increased fibrinolysis and the thrombocyto-
penia, it was decided to administer a second 100ml
dose of antivenom (Favirept, Pasteur Me´rieux
Lyon-France, fragments F(ab/)2 d’immunoglobulines
e´quines antivenimeuses de Bitis, Echis, Naja,
Cerastes et Macrovipera) on day 4, 80 h after the
snakebite. Before antivenom administration, the
patient received 100mg of prednisolone intrave-
nously, 2mg of clemastine (a histamine anti-H1
blocker) intravenously and 0.25mg epinephrine
subcutaneously as prophylaxis against anaphylactic
reactions. The following morning, the patient
noticed difficulty in picking up a cup and reading
the newspaper. Ophthalmoscopy excluded a retinal
lesion but, 16 days later, after he had been
transferred back to Chur, an MRI revealed an
intracerebral haemorrhage in the occipital region
(Figure 3).
During the next 10 days, the patient’s haemo-
globin concentration increased steadily, and the
thrombocytopenia resolved completely (Table 1).
Haemodialysis was maintained until the proteinuria
decreased to <1 g/day after 37 days. His renal func-
tion continued to improve, returning to normal for
him two months after the bite. Twenty months
after the snakebite, the patient was well with no
sequelae.
Patient 2
A 43-year-old unemployed snake enthusiast was
admitted to a hospital in Sheffield, UK at 1030 h on
18 September 1998, complaining of increasing pain
and swelling of the right arm. About 20 h earlier,
he had been bitten on the right index finger by
a Saharan horned-viper (C. cerastes), said to be
from North Africa, while negotiating its purchase
in London. Initially, there was some pain and local
swelling but after drinking heavily, he slept for
most of the train journey back to Sheffield. He was
Figure 3. Patient 1: MRI scan taken 16 days after he
developed symptoms of a stroke (courtesy of Dr Brunner,
Kantonsspital Chur, Switzerland).
Table 1 Patient 1: changes in haematological variables after antivenom treatment
Days after bite 1 2 3 4 5 6 7 8 9 10 11 NR
Antivenom  
Haemoglobin (g/l) 154 104 90 75 66 75 65 82 78 79 72
Platelets (109/l) 67 24 29 13 32 25 44 68 113 161 173
Prothrombin time (%) 10 32 55 95 100 105 108 105 100 100
Factor V (%) 2 59 70 102 109 116 50–100%
Fibrinogen (g/l) U 1.06 2.5 3.04 4.01 3.9 3.17 3.87 2.6 4.48
D-dimer (mg/ml) 0.25 0.45 17.58 12.11 8.05 5.62 2.92 3.85 0.3 <0.2
U, Undetectable; NR, normal range.
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awoken by pain 11 h after the bite. On admission,
he was complaining of increasing pain, swelling
and bruising in the bitten limb. He had felt short of
breath after walking up a slope to the hospital. There
were two fang punctures on the knuckle of his right
index finger and gross tender swelling of the entire
right arm from fingers to the shoulder-tip. There was
bruising in the antecubital fossa but no other evi-
dence of bleeding, his blood pressure was normal
and he was still passing some urine. There were no
other abnormal physical signs. The ECG was normal
apart from a sinus tachycardia of 110 bpm. The
haemoglobin concentration was normal, there was
thrombocytopenia (Table 2), leukocyte count 18.2
109/l (neutrophils 15.9), prothrombin time 23.9 s
(INR 1.92, laboratory normal range 11–15 s), APTT
39 s (28–38 s), thrombin time 14 s (9 s), fibrinogen
concentration reduced with elevated D-dimers
(Table 2). The serum C. cerastes venom antigen
concentration was 5.6 ng/ml at 1200 h (21 h after
the bite). Urethral catheterization yielded only a few
ml of dark urine. There was evidence of free haemo-
globin in his blood and urine (Figure 4). The blood
film showed red cell fragmentation, crenation and
microspherocytes (Figure 5a). Plasma sodium
141mmol/l, potassium 6.1mmol/l, urea and creati-
nine elevated (Table 2), bilirubin 73mmol/l, crea-
tine kinase 401, myoglobin 700. Twenty-two and
a half hours after the bite, C. cerastes venom anti-
gen concentration was 28.2 ng/ml. After consulta-
tion with DAW, 10 ampoules of Behringwerke
Near and Middle East polyspecific antivenom were
administered 23–24 h after the bite and, in view of
his deteriorating renal function, he was admitted to
the Renal Unit. A femoral dialysis line was inserted
under the cover of an infusion of platelets and
cryoprecipitate. Five hours after starting antivenom,
C. cerastes venom antigen was undetectable in his
serum. Prothrombin time (12 s), APTT (33 s), and
fibrinogen had returned to normal, levels of D-dimer
had dropped and the platelet count had risen
(Table 2). Over the next three days, his haemo-
globin concentration and platelet count fell, and
there was continuing deterioration in his renal
function (Table 2). A second dose of 10 ampoules
of the same antivenom was therefore given 4 days
after the bite. After this there was a sustained
increase in platelet count. He was given haemodial-
ysis 4, 6 and 11 days after the bite. Morphological
evidence of microangiopathic haemolysis persisted,
the changes becoming more severe on the day after
the first antivenom treatment (Figure 5b). Impressed
by further falls in haemoglobin concentration and
platelet count 4–8 days after the bite together with
the blood film appearances of red cell fragmentation
with many burr cells (Figure 5c), the nephrologists
postulated haemolytic uraemic syndrome and con-
templated renal biopsy and plasma exchange.
However, his urine output and renal function
improved consistently over the next few days. He
was discharged from hospital 20 days after the
bite. Thirty-seven days after the bite, the swelling
of his arm was resolving, although the digits
were still swollen and stiff. Red cell fragmentation
was still evident on the blood film, his haemoglobin
was 11.0 g/dl, platelets 157 109/l, urea 6.9mmol/l,
creatinine 132 mmol/l. Subsequently, all these
abnormalities resolved completely.
Discussion
There is a small literature on envenoming by
desert horned vipers. Identification is facilitated by
the distinctive supraorbital ‘horns’ (Figure 1), which
make this snake virtually unmistakable. Severe
and even fatal envenoming by C. cerastes was
reported in the 19th century. Chavasse (1891)
provided what is probably the only account of
a fatal bite by this species.21 A 28-year-old man
was bitten twice on the index finger by a horned
viper near Laghouat oasis, 400 km south of Algiers.
After four days of traditional treatment, he presented
Table 2 Patient 2: changes in haematological variables and renal function after antivenom treatment
Days after bite 0 1 2 3 4 5 6 7 8 9 10 11 12 NR
Antivenom  
Haemoglobin (g/l) 155 113 101 84 82 65 72 62 80 72 73 69 79
Platelets (109/l) 65 114 62 42 73 101 200 245 280 342 315 334 246
Fibrinogen (g/l) 0.45 2.14 4.08 4.39 4.53 5.26 4.46 3.97 4.7 4.7 4.83 1.8–4.0
D-dimer (mg/ml) 128 64 8 8 6 3 6 6 6 6 4 <0.2
Urea (mmol/l) 13.3 28.6 33.8 32.0 41.6 47.2 37.4 41.7 25.7 33.8 25.5 29.8 25.1
Creatinine
(mmol/l)
355 754 903 923 1098 1370 1123 1319 878 1054 899 1087 879
NR, normal range.
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with vomiting, sweats, severe headache, epistaxis
and red urine. He was febrile, jaundiced and
collapsed with tachypnoea, tachycardia, swelling
of the entire bitten arm and painful, enlarge-
ment of lymph nodes. Over the next few days, the
bitten finger became gangrenous with a purulent
discharge; the patient experienced persistent diar-
rhoea and died one week after the bite. Corkill
reviewed snakes and snake bites in Iraq (1932)3 and
the Sudan (1935).18 He mentioned two anecdotal
fatalities from Dohuk and Baghdad, in one of
which the patient died 24 h after the bite with mass-
ive swelling of the bitten arm. The usual symptoms
were marked swelling and necrosis followed by
indolent sepsis in the neighbourhood of the bite,
but with a notable absence of the haemor-
rhagic symptoms typical of viperine envenoming.3
Guyon (1862) described two cases in Laghouat,
Algeria treated by local incisions and instillation
and ingestion of ammoniacals.22 One man, bitten
on the foot, had been subjected to a traditional
remedy of having the bitten part placed inside the
abdomen of a freshly-killed dog. He developed
local swelling up to the knee and, 4 days later,
hemiparesis and difficulty speaking, attributable to
a stroke. The other, who was bitten on the buttock
while sleeping in his tent, coughed up blood a few
hours later. Schaumont (1883) treated three cases
in Algeria with local instillation of an opiate-ether
potion.23 Only one of them developed signs of
local envenoming. Driout (1883) in southern Algeria
advocated potassium permanganate treatment after
demonstrating its efficacy in dogs, goats and birds
bitten by horned-vipers.24 Escard (1889) admitted
a patient who had been bitten on the little toe 24 h
earlier by a ‘le´faˆ’ (C. cerastes) in Algeria.25 The
bitten limb was red with purplish blotches and was
tensely swollen right up to the inguinal ligament.
There were blisters containing yellowish fluid and
a hydrarthrosis of the knee. Despite repeated injec-
tions of potassium permanganate into the limb,
all the symptoms had disappeared after 12 days.
Calmette (1908) reported a 26-year-old man who
was bitten on the finger by a horned-viper 50 cm
in length near Laghouat, Algeria.16 He was treated
with Calmette’s non-specific antivenomous serum
and with injections of potassium permanganate
and, over the next few days, developed tense
swelling and ecchymoses of the arm and adjacent
area of the trunk but survived. A number of cases
of C. cerastes envenoming have been described in
Israel. Efrati (1979) noted that the clinical features
in seven cases were similar to mild envenoming
by Vipera palaestinae. One patient developed
necrosis requiring amputation of a finger.26 Systemic
symptoms were mild, comprising nausea and
vomiting in most patients, with skin haemorrhages
and haematuria in four. Evidence of coagulopathy
(hypofibrinogenaemia and prolongation of pro-
thrombin time) was less severe than in victims of
Echis coloratus envenoming. Path and Ravid (1971)
reported a 20-year-old man bitten on the finger who
showed transient tachycardia, decrease in haemo-
globin concentration (9.4 g/dl), thrombocytopenia
Figure 4. Patient 2: on admission to hospital, sponta-
neously sedimented blood showing haemoglobinaemia
(right), compared to a control.
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(98 109/l) and depletion of clotting factors (pro-
thrombin time 20%, thrombin and APPT mildly
prolonged), who was admitted 8 h after the bite.27
There was marked swelling of the bitten hand and
arm, and a local haemorrhagic blister, which turned
necrotic. Shargil et al. (1973) described six cases of
C. cerastes bite admitted to hospital in Tel Aviv.28
Most of the patients had applied tourniquets, and
Figure 5. Patient 2: blood smear showing fragmented erythrocytes, evidence of microangiopathic haemolysis: A on
admission to hospital 20 h after the bite; B 44 h after the bite; and C 7 days after the bite.
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three developed necrosis of bitten fingers, requiring
amputation in one. Common systemic symptoms
were nausea, abdominal pain and sweating. Hae-
matemesis was recorded in one and haematuria in
four cases. Four were treated with specific (Pasteur)
antivenom, five were mildly anaemic at some stage,
three had peripheral leukocytosis, three thrombo-
cytopenia, while three showed a mild coagulo-
pathy. A 17-year-old man bitten on the finger
was admitted to hospital in Beer-Sheva, with local
swelling, haemorrhagic blister and necrosis which
required skin grafting. There was upper abdominal
pain and vomiting. He had a leukocytosis of 15.4
109/l and coagulopathy attributed to disseminated
intravascular coagulation.29 An 18-year-old woman
also treated at Beer-Sheva had been bitten on the
finger while playing with a C. cerastes. There was
swelling which eventually involved the whole
arm, bleeding from the fang marks and from veni-
puncture wounds, incoagulable blood (indefinitely
prolonged prothrombin and partial thromboplastin
times), thrombocytopenia and a haemoglobin
concentration of only 9.1 g/dl, mild erythrocyte
anisocytosis but no visible schistocytes. She was
treated only with fresh frozen plasma and eventually
made a full recovery. Renal and hepatic functions
had remained normal.30 Chippaux (1982) found that
bites by these species were characterized by local
inflammatory reaction and swelling which, how-
ever, showed little tendency to spread, unusually
acute pain and a tendency to develop local necrosis
as early as three or four hours after the bite.31 About
a dozen cases of bites by the Saharan sand viper
(Cerastes vipera) have been reported.32,33 This
species, which is much smaller than the desert
horned vipers (maximum length 35 cm com-
pared to 90 cm), is capable of causing mild local
and systemic envenoming but local necrosis,
renal failure and systemic bleeding have not been
observed.
Against this background of reported experience
of C. cerastes bites, both the cases reported here,
inflicted in Europe by captive Saharan horned vipers,
were surprising for the life-threatening severity of
envenoming. Like many other published cases, both
patients developed massive swelling of the bitten
limb, with bruising and, in Patient 1, a small area
of necrosis. However, unlike the reported cases,
both our patients showed evidence of profound
coagulopathy, fibrinolysis and thrombocytopenia
associated with haemolytic anaemia attributable
to microangiopathic haemolysis. In both cases, there
was acute renal failure requiring prolonged haemo-
dialysis. In Patient 2, the clinical picture raised
the possibility of haemolytic-uraemic-syndrome
(HUS), but the evidence of marked coagulopathy
in both cases strictly excludes this diagnosis.34–36
How can the clinical findings in our cases be
explained by what is known of the composition of
C. cerastes venom? More than 30 studies have been
Figure 5. Continued.
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published on C. cerastes venom and, so far, more
than 13 different toxins have been identified.37
These include serine proteases and other thrombin-
like enzymes (fibrinogenases) (IVa, Cerasto-
cytin,38,39 Cerastotin,40 RP3 4, Afaaˆcytin41 and
Cerastase F-4), which are likely to be responsible
for causing hypofibrinogenaemia in human victims;
activators of platelet aggregation/agglutination
(Cerastocytin, Cerastotin), which could cause
thrombocytopenia and endothelial activation; inhib-
itors of platelet aggregation (IVa, Cerastatin,42
Cerastin), which could contribute to a bleeding
tendency; Factor X activators (calcium-dependent
and calcium-independent serine proteases, Afaaˆcy-
tin), which could result in disseminated intravascu-
lar coagulation; a haemorrhagic protease (Cerastase
F-4), which could cause spontaneous systemic
bleeding; a protein C activator exerting a possible
anticoagulant effect; and an a/b fibrinogenase,
which releases serotonin from platelets (Afaaˆcytin);
a phosphodiesterase exonuclease and a weakly
toxic phospholipase A2, which could contribute
to local tissue damage.
Since some of these toxins exert opposing actions,
the net effect, for example on platelets, may depend
on the composition of the venom injected by a
particular snake on a particular occasion. The large
intraspecies variation in venom composition is
now well recognized43 and geographical variation
in C. cerastes venom has been documented.44 This
has obvious implications for antivenom production
and efficacy.
Micro-angiopathic haemolysis was a striking
feature of both our cases (Figure 5). It is attributable
to vascular endothelial damage and thrombin
deposition on the walls of blood vessels, resulting
in the distortion, damage and destruction of circu-
lating erythrocytes. A direct action of venom
enzymes, such as the phospholipase A2, may have
contributed to erythrocyte damage.
Acute renal failure is an expected consequence
of this process, but in rats, the effects of sub-lethal
doses of C. cerastes venom were interpreted as
causing mesangial proliferative glomerulonephritis
leading to acute tubular necrosis by direct nephro-
toxicity and ischaemia. There was cortical necrosis
resulting from thrombosis and bleeding.45 However,
in neither of our patients was renal biopsy justified,
and so we have no information about histopatholog-
ical changes.
In Patient 1, heparin was given for 24 h in
an attempt to inhibit venom thrombin activity.
However, the use of heparin as an ancillary
treatment for snake-venom-induced coagulopathy
is highly controversial. Thrombin-like activities
of venoms are not inhibited by heparin,46 and it
has never been proved effective in clinical trials,47
even in victims of Russell’s vipers (Daboia russelii
and D. siamensis) envenoming in whom there is
some slight theoretical basis for its use.48 Heparin
increases the risk of haemorrhage in victims of viper
bites and should never be risked in the treatment
of these patients.49 Our Patient 1, who had pre-
existing hypertension and peripheral vascular dis-
ease affecting the femoral and cerebral arteries,
with a history of a previous stroke, developed
neurological symptoms on the fourth day after the
bite. Cerebral haemorrhage was later confirmed
by MRI (Figure 3). There is a report of a stroke
directly attributable to C. cerastes envenoming,22
but our patient’s symptoms appeared at a time when
the anti-haemostatic effects of envenoming and
circulating level of venom had been controlled by
two substantial doses of antivenom. This was about
48 h after heparin treatment had been stopped, but
was temporally related to the administration of
0.25mg of epinephrine subcutaneously as prophy-
laxis against an antivenom reaction.50 In Australia,
there was an inconclusive debate about the role of
epinephrine in haemorrhagic strokes complicating
bites by tiger and brown snakes.51 Premawardhena
et al. (1999)50 have qualified their earlier recom-
mendation of routine prophylaxis with sub-cuta-
neous epinephrine, based on a controversial study,52
after a patient suffered a fatal stroke 10 h following
epinephrine treatment.53 His pre-existing pathology
would have rendered our patient vulnerable to this
rare complication of epinephrine, but causation is
unproven.
In both of our patients, use of large doses
of polyspecific antivenom with activity against
C. cerastes venom proved decisive in curtailing
the coagulopathy, but did not prevent the evolution
of profound renal failure. This was also the case in
victims of Russell’s viper (Daboia siamensis) bite
in Myanmar, even when antivenom was adminis-
tered within 1–2 h of envenoming.48
This clinical study has demonstrated the ability
of C. cerastes to cause complicated and potentially
fatal envenoming, a warning to those exotic-snake
enthusiasts who keep this species in captivity, and
to those who live, work, travel and go to war in its
extensive eremic domain.
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